Blood-based biomarkers are set to make biological assessment of Alzheimer's disease much quicker and more accessible than has been possible with imaging and CSF biomarkers. Does this mean the disease now be defined as a purely biological entity?

Dr. Nicolas Villain outlines why it is still so important to consider both clinical symptoms and biological findings when making a diagnosis.